Quarterly report pursuant to Section 13 or 15(d)

Condensed Statement of Shareholders' Equity (Unaudited)

v3.22.1
Condensed Statement of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Common Stock [Member]
Common Stock [Member]
Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Additional Paid in Capital [Member]
Additional Paid in Capital [Member]
Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect, Period of Adoption, Adjusted Balance [Member]
Beginning balance at Dec. 31, 2020   $ 36,216   $ 10   $ 243,484   $ (207,278)
Beginning balance, Shares at Dec. 31, 2020       100,016,559        
Issuance of common stock upon exercise of stock options Value $ 30       $ 30      
Issuance of common stock upon exercise of stock options Shares     2,112,373          
Vesting of early exercised stock options 24       24      
Repurchase of unvested restricted common stock, Shares     (87,768)          
Issuance of Series D convertible preferred stock upon exercise of warrants 20,877       20,877      
Issuance of Series D convertible preferred stock upon exercise of warrants Shares     2,020,034          
Stock-based compensation 1,555       1,555      
Net income (loss) (16,165)           $ (16,165)  
Ending balance at Mar. 31, 2021 42,537   $ 10   265,970   (223,443)  
Ending balance, Shares at Mar. 31, 2021     104,061,198          
Beginning balance at Jan. 02, 2022 $ 326,117   $ 15   659,254   (333,152)  
Beginning balance, Shares at Jan. 02, 2022 152,272,287   152,272,287          
Issuance of common stock upon exercise of stock options Value $ 200       200      
Issuance of common stock upon exercise of stock options Shares 91,910   91,910          
Issuance of common stock upon exercise of common stock warrants $ 47,452       47,452      
Issuance of common stock upon exercise of common stock warrants, Shares     4,126,466          
Vesting of early exercised stock options 42       42      
Vesting of restricted stock units     34,941          
Repurchase of unvested restricted common stock, Shares     (105,886)          
Stock-based compensation 4,536       4,536      
Net income (loss) 42,707           42,707  
Ending balance at Apr. 03, 2022 $ 421,054   $ 15   $ 711,484   $ (290,445)  
Ending balance, Shares at Apr. 03, 2022 156,419,718   156,419,718